{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T12:14:48Z","timestamp":1753877688701,"version":"3.41.2"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T00:00:00Z","timestamp":1750982400000},"content-version":"vor","delay-in-days":26,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Late recurrence of ovarian cancer is exceedingly rare. We report a case of adenocarcinoma of M\u00fcllerian origin that developed 22\u00a0years after hysterectomy and bilateral salpingo-oophorectomy (BSO) for ovarian cancer in an 81-year-old woman with a pathogenic BRCA1 mutation. The patient underwent six cycles of reduced-dose carboplatin and paclitaxel, achieving remission with a dramatic decline in CA-125 levels. Women with BRCA mutations have a significantly increased risk of ovarian\/tube\/peritoneal cancer. Although risk-reducing BSO effectively decreases the risk of ovarian and fallopian tube cancers, the risk of peritoneal cancer remains substantial. This case not only illustrates the persistent lifetime risk of ovarian\/tube\/peritoneal cancer despite BSO but also underscores the need for reevaluation of prophylactic surgical strategies, particularly regarding the extent of peritoneal resection, in BRCA mutation carriers. Additionally, this case report demonstrated the efficacy of dose-modified chemotherapy for BRCA-associated cancers. Further research is warranted to refine surgical and therapeutic strategies for patients with BRCA mutation.<\/jats:p>","DOI":"10.1093\/omcr\/omaf075","type":"journal-article","created":{"date-parts":[[2025,6,27]],"date-time":"2025-06-27T04:58:10Z","timestamp":1751000290000},"source":"Crossref","is-referenced-by-count":0,"title":["Adenocarcinoma of M\u00fcllerian origin developed 22\u00a0years after Salpingo-oophorectomy in a woman with BRCA1 mutation: a thought about modification of chemotherapy dose and peritoneal resection"],"prefix":"10.1093","volume":"2025","author":[{"given":"Stanley","family":"Kim","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology, Kern Medical Center , Bakersfield, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Schaerth","sequence":"additional","affiliation":[{"name":"Division of Gynecological Oncology, Kern Medical Center , Bakersfield, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin","family":"Chen","sequence":"additional","affiliation":[{"name":"Medical Student, Western University of Health Science-College of Osteopathic Medicine of the Pacific , Pomona, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Stull","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kern Medical Center , Bakersfield, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gian","family":"Yakoub","sequence":"additional","affiliation":[{"name":"Department of Pathology, Kern Medical Center , Bakersfield, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,6,27]]},"reference":[{"key":"2025062806572519000_ref1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1001\/jama.2017.7112","article-title":"Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers","volume":"317","author":"Kuchenbaecker","year":"2017","journal-title":"JAMA"},{"key":"2025062806572519000_ref2","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1001\/jama.296.2.185","article-title":"Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 mutation","volume":"296","author":"Finch","year":"2006","journal-title":"JAMA"},{"key":"2025062806572519000_ref3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.critrevonc.2019.05.014","article-title":"Ovarian cancer relapse: from the latest scientific evidence to the best practice","volume":"140","author":"Luvero","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"2025062806572519000_ref4","doi-asserted-by":"publisher","first-page":"3938833","DOI":"10.1155\/2024\/3938833","article-title":"Late recurrence of ovarian cancer after 18 years of disease-free survival: a case report and review of the literature. Case rep","volume":"2024","author":"Suzuki","year":"2024","journal-title":"Obstet Gynecol"},{"key":"2025062806572519000_ref5","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1002\/ijgo.13878","article-title":"Cancer of the ovary, fallopian tube, and peritoneum: 2021 update","volume":"155","author":"Berek","year":"2021","journal-title":"Int J Gynaecol Obstet"},{"key":"2025062806572519000_ref6","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/j.1365-2559.2004.01787.x","article-title":"WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma","volume":"44","author":"Al-Hussaini","year":"2004","journal-title":"Histopathology"},{"key":"2025062806572519000_ref7","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1200\/JCO.21.02016","article-title":"Risk of peritoneal Carcinomatosis after risk-reducing Salpingo-oophorectomy: a systematic review and individual patient data meta-analysis","volume":"40","author":"Steenbeek","year":"2022","journal-title":"J Clin Oncol"},{"key":"2025062806572519000_ref8","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1093\/jnci\/djae151","article-title":"Incidence of peritoneal cancer after oophorectomy among BRCA1 and BRCA2 mutation carriers","volume":"116","author":"Narod","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"2025062806572519000_ref9"},{"key":"2025062806572519000_ref10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1093\/annonc\/mdq628","article-title":"Chemosensitivity and outcome of BRCA1- and BRCA2-associated ovarian cancer patients after first-line chemotherapy compared with sporadic ovarian cancer patients","volume":"22","author":"Vencken","year":"2011","journal-title":"Ann Oncol"}],"container-title":["Oxford Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/6\/omaf075\/63596125\/omaf075.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/omcr\/article-pdf\/2025\/6\/omaf075\/63596125\/omaf075.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,28]],"date-time":"2025-06-28T10:57:35Z","timestamp":1751108255000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/omcr\/article\/doi\/10.1093\/omcr\/omaf075\/8175748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":10,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6,27]]}},"URL":"https:\/\/doi.org\/10.1093\/omcr\/omaf075","relation":{},"ISSN":["2053-8855"],"issn-type":[{"type":"electronic","value":"2053-8855"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,6]]},"article-number":"omaf075"}}